Promising Data on ONCY's Reolysin - Analyst Blog

By
A A A

Recently, Oncolytics Biotech Inc. ( ONCY ) reported positive preliminary results from the US phase II trial (REO 020) evaluating the use of oncology candidate, Reolysin in combination with Bristol-Myers Squibb 's ( BMY ) Taxol (paclitaxel) and carboplatin, which are widely used chemotherapy treatment. The phase II trial aims to assess the safety and efficacy profile of Reolysin in patients suffering from metastatic melanoma.

The study enrolled second-line or third-line metastatic malignant melanoma patients. Patients for whom the standard first line treatment was considered unsuitable were also enrolled. In the first stage of the phase II trial, 3 of the 14 metastatic melanoma patients demonstrated partial response (PR). Additionally, 7 patients exhibited stable disease with a disease control rate of 71.5%.

We are pleased with the preliminary results from the phase II trial, which supports the candidate's progression into the second stage. The primary endpoint of the phase II trial is to evaluate the treatment regimen's anti-tumour effect. The secondary endpoints include the evaluation of progression-free survival and overall survival, disease control rate, safety and tolerability.

Investors have reacted positively to the encouraging preliminary data on Reolysin.

We note Oncolytics Biotech is developing Reolysin as monotherapy or in combination with chemotherapy and radiotherapy for several oncology indications, including head and neck cancers (phase III), pancreatic cancer (phase II) and non-small cell lung cancer (phase II).

Oncolytics Biotech carries a Zacks Rank #2 (Buy). Right now, Anika Therapeutics,Inc. ( ANIK ) and Jazz Pharmaceuticals Public Limited Company ( JAZZ ) look more attractive. Both stocks carry a Zacks Rank #1 (Strong Buy).



ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

BRISTOL-MYERS (BMY): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

ONCOLYTICS BIO (ONCY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ANIK , BMY , JAZZ , ONCY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

89,070,840
  • $17.26 ▲ 3.23%
78,931,485
  • $7.02 ▲ 4.46%
77,555,734
  • $6.70 ▲ 6.69%
77,025,346
  • $24.66 ▲ 0.69%
74,713,335
  • $101.80 ▲ 1.82%
72,324,726
  • $7.64 ▲ 0.79%
57,112,188
  • $17.84 ▲ 55.27%
53,321,397
  • $18.01 ▼ 4.46%
As of 12/17/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com